IFUL Insightful Corp (MM)

Insightful Corporation (NASDAQ:IFUL), a leading provider of predictive analytics and reporting solutions, announced today the release and immediate availability of version 1.1 of Insightful Clinical Graphics (iCG), a product for defining and repurposing statistical graphics across all functional areas in drug discovery, development and marketing. iCG 1.1 features new graph types and an improved user experience. Pharmaceutical companies currently starting projects with iCG 1.1 include H.�Lundbeck A/S in Denmark. �Many global pharmaceutical companies are looking to integrate graphics into their clinical trials process, making iCG one of our most significant life science solutions to date,� said Jeff Coombs, CEO of Insightful. �With iCG, customers save time and resources, perform better scientific analysis and interpretation, and communicate more effectively with internal and external stakeholders.� With input from multiple life sciences companies, Insightful designed iCG to simplify the creation and re-use of statistical graphics and elimination of redundant work processes. From discovery, pre-clinical and clinical trials, through marketing and epidemiology, iCG enables scientific data to be presented as actionable information in clinical study reports, regulatory submissions, publications and presentations. iCG helps optimize the deployment of expensive statistical programming resources by allowing non-programming statisticians, clinicians and medical writers to apply customizable graph templates to study data and to change a graph style, without compromising the data or the results displayed. Key Features and Enhancements iCG 1.1 contains a number of significant enhancements: Expanded 2D graph palette, including bubble, delta, cumulative incidence and double dot plots Support for 3D graph types, including contour and image plots Added plug-in customization of graph palette, graph metadata and workflow Improved user experience and system performance Reduced dependence on Information Technology staff Insightful Life Sciences Solutions Provide the Knowledge to Act� Insightful provides life sciences organizations with the knowledge they need to drive faster, better decisions, with specialized analytics, graphics and reporting. Insightful offers software and service solutions in statistical graphics, PK/PD analysis and reporting, clinical data review, clinical trial design, and safety data analysis. These solutions are designed to integrate with existing data management and workflow systems in exploratory and validated environments, to speed the analysis and reporting processes and increase the likelihood of discerning safety and efficacy signals earlier in the drug development process, thus decreasing customers� product development costs and time to market. ABOUT INSIGHTFUL Insightful Corporation (NASDAQ:IFUL) is a provider of predictive analytics and reporting solutions. Insightful products S-PLUS�, Insightful Miner� and S-PLUS� Enterprise Server allow companies to perform sophisticated statistical data analysis and data mining and create high-quality graphics and reports. Insightful has been delivering industry-leading, high-ROI solutions to thousands of companies in financial services, life sciences, telecommunications, and manufacturing, plus government and research institutions, for 20 years. Headquartered in Seattle, Insightful has offices in New York, North Carolina, Switzerland, the United Kingdom, France and Hong Kong, with distributors around the world. For more information, visit www.insightful.com, email info@insightful.com or call 1-800-569-0123. Note to Investors � Forward Looking Statements This press release contains forward-looking statements, including statements about the potential performance and advantages of iCG and other life sciences solutions and their potential value to customers. Forward-looking statements are based on the judgment and opinions of management at the time the statements are made. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from those expressed or implied by the forward-looking statements for a number of reasons, including, without limitation, the risk that our products do not perform as designed and expected and the risk that our products do not achieve market acceptance. More detailed information regarding these and other factors that could affect actual results is set forth in our filings with the Securities and Exchange Commission, including our most recent report on Form 10-KSB. You should not unduly rely on these forward-looking statements, which apply only as of the date of this release. We undertake no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of anticipated events.